Rituximab Offlabel denied as not medically necessary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for rituximab offlabel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied This Rituximab Claim as Not Medically Necessary

A medical-necessity denial for off-label rituximab typically means BCBS reviewed the submitted clinical information and concluded that the available documentation did not demonstrate your case meets the clinical criteria defined in its coverage policy. This is not necessarily a judgment that the drug is wrong for you — it often reflects a documentation gap rather than a true clinical disagreement.

Because medical-necessity determinations are fact-specific and heavily documentation-driven, they are among the most successfully appealed denial types when the clinical record is properly organized and presented.

## Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 (job-based plans) you are entitled to a full-and-fair review with access to the specific clinical criteria used in the denial decision. Request the complete denial rationale and the clinical guidelines or coverage policy the reviewer applied.
• External review: Under ACA §2719, if your internal appeal is denied you may request an IRO review, generally within four months of the final internal denial.
• Expedited option: If your condition is urgent or a standard timeline would worsen your health, request expedited review in writing.

## Documentation to Gather

1. Diagnosis confirmation — chart notes from the treating and consulting specialists, with dates, establishing the specific diagnosis and its severity or staging. 2. Prior-treatment history — a complete chronological list of every prior therapy, including start dates, stop dates, doses (from the prescribing record), and the documented reason each was discontinued or deemed inadequate. BCBS policies often require evidence of an adequate trial of one or more prior agents. 3. Clinical severity documentation — objective measures from the chart (clinician-recorded disease activity scores, functional assessments, organ-involvement notes) demonstrating why the condition warrants this level of treatment. 4. Prescriber medical-necessity letter — your physician should address each criterion in BCBS's published coverage policy for this off-label use, citing the chart record for each. 5. Applicable guideline reference — your prescriber should note the specialty-society guideline organization that supports rituximab for your condition (e.g., ACR, ASH, relevant subspecialty society).

## Criteria-Mapping Structure

Download BCBS's current medical/coverage policy for rituximab and your diagnosis. For every listed requirement, draft a one-sentence response that names the exact document, date, and finding from your chart that satisfies it. Your prescriber's letter should mirror this structure — criterion by criterion — so the reviewer can verify compliance without searching through unorganized records.